Reports

Drug name	NICE TAs	Comments
Patiromer (Veltassa®)	TA623 - Patriomer for treating hyperkalaemia	In emergency care for acute life-threatening hyperkalaemia alongside standard care
Patiromer (Veltassa®)#Amber	TA623: Patiromer for treating hyperkalaemia	RICaD: Patiromer for treating hyperkalaemia
Pediacel		Supported with PGD
Pegaspargase injection	TA408 - Pegaspargase for treating acute lymphoblastic leukaemia	For hospital use only
Pegfilgrastim injection		QEHB site only
Peginterferon Alfa-2A (Pegasys)		Myeloproliferative neoplasia (MPN)
Pembrolizumab (Keytruda®)	TA357 - Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab TA366 - Pembrolizumab for advanced melanoma not previously treated with ipilimumab TA428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy TA519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA522 - Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable TA531 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TA540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma TA553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA661 - Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA709 - Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma TA851 - Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer TA914 - Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma [TA983] Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma [TA997] Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer [TA737]	For hospital use only
Pemetrexed injection	TA190 - Pemetrexed for the maintenance treatment of non-small-cell lung cancer TA181 - Pemetrexed for the first-line treatment of non-small-cell lung cancer TA135 - Pemetrexed for the treatment of malignant pleural mesothelioma TA309 - Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer TA124 - Pemetrexed for the treatment of non-small-cell lung cancer TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer	For hospital use only. Negative TA (124)
Penecillamine tablets		ESCA
Penicillamine		Specialist recommendation for Wilson disease. Supported with an ESCA (in development).

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports